Cardiovascular Effects of 3 Months of Treatment with GLP-1 Receptor Agonist Exenatide and DPP-4 Inhibitor Linagliptin: The SAFE-GUARD Trial

MLA

Mraz, Milos, et al. Cardiovascular Effects of 3 Months of Treatment with GLP-1 Receptor Agonist Exenatide and DPP-4 Inhibitor Linagliptin: The SAFE-GUARD Trial. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..4e957dacd3673497ca844ac75e055cdb&authtype=sso&custid=ns315887. Accessed 3 Mar. 2025.

APA

Mraz, M., Chytilova, E., Klouckova, J., Trachta, P., Skrha, J., Krizova, J., Petrak, O., Krupicka, J., Tuka, V., Jaroslav Kudlicka, Kratka, Z., Dostalova, G., Malik, J., & Haluzik, M. (n.d.). Cardiovascular Effects of 3 Months of Treatment with GLP-1 Receptor Agonist Exenatide and DPP-4 Inhibitor Linagliptin: The SAFE-GUARD Trial.

Chicago

Mraz, Milos, Eva Chytilova, Jana Klouckova, Pavel Trachta, Jan Skrha, Jarmila Krizova, Ondrej Petrak, et al. 2025. “Cardiovascular Effects of 3 Months of Treatment with GLP-1 Receptor Agonist Exenatide and DPP-4 Inhibitor Linagliptin: The SAFE-GUARD Trial.” Accessed March 3. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..4e957dacd3673497ca844ac75e055cdb&authtype=sso&custid=ns315887.